This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Dana-Farber-Cancer Institute Inc., The Brigham and Women's Hospital, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,269 
1 out of 1,430 
Years Active: 2024
Title: Israel Cañadas: Cancer Immunotherapy Biomarker Inventor
Introduction
Israel Cañadas is an inventor based in Brookline, Massachusetts. His work includes research into biomarkers that may help guide cancer immunotherapy.
Latest Patents
Cañadas is associated with 1 patent, titled “STING Levels as a Biomarker for Cancer Immunotherapy.” The patent describes Stimulator of Interferon Genes (STING) and Stimulated 3 Prime Antisense Retroviral Coding Sequences (SPARCS) genes as biomarkers for identifying effective cancer treatments. It also describes methods for treating cancer using these biomarkers.
Career Highlights
Cañadas has been associated with The Brigham and Women’s Hospital and Dana-Farber Cancer Institute. His patent reflects research focused on applying biological markers to cancer treatment decisions.
Collaborations
His listed coworkers include David Barbie and Shunsuke Kitajima, whose work is also connected to cancer research.
Conclusion
Israel Cañadas’s patent highlights the potential role of STING and SPARCS biomarkers in selecting and developing cancer immunotherapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile